Asthma medication receives new warning /
Aschenbrenner, Diane S.
Asthma medication receives new warning / Diane S. Aschenbrenner - January 2015 - American Journal of Nursing 115 : 1, page 22-23 .
The Food and Drug Administration has revised the warnings in the labeling of omalizumab (Xolair), a drug used in the treatment of allergic asthma. Omalizumab's labeling now warns that the drug may carry a slightly elevated risk of cardiovascular complications. Omalizumab is administered every two to four weeks as a subcutaneous injection to patients with moderate-to-severe persistent, allergic asthma and an elevated IgE level and whose allergic asthma symptoms aren't well controlled with corticosteroids.
Nursing
0002-936X
Labeling.
Cardiovascular diseases.
Antiallergic agents.
Cancer.
Asthma.
Drugs.
Descriptive labeling.
Asthma medication receives new warning / Diane S. Aschenbrenner - January 2015 - American Journal of Nursing 115 : 1, page 22-23 .
The Food and Drug Administration has revised the warnings in the labeling of omalizumab (Xolair), a drug used in the treatment of allergic asthma. Omalizumab's labeling now warns that the drug may carry a slightly elevated risk of cardiovascular complications. Omalizumab is administered every two to four weeks as a subcutaneous injection to patients with moderate-to-severe persistent, allergic asthma and an elevated IgE level and whose allergic asthma symptoms aren't well controlled with corticosteroids.
Nursing
0002-936X
Labeling.
Cardiovascular diseases.
Antiallergic agents.
Cancer.
Asthma.
Drugs.
Descriptive labeling.